Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company
06. Januar 2025 05:00 ET
|
Portage Biotech Inc.
Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company
Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd
17. Dezember 2024 07:00 ET
|
Portage Biotech Inc.
Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd
Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter
12. Dezember 2024 16:15 ET
|
Portage Biotech Inc.
Portage Biotech announces receipt of Nasdaq noncompliance letter
Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024
26. November 2024 16:05 ET
|
Portage Biotech Inc.
Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update
27. August 2024 08:00 ET
|
Portage Biotech Inc.
WESTPORT, Conn., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted...
Portage Biotech Reports Fiscal Year-Ended March 31, 2024 Financial Results and Business Update
15. August 2024 07:00 ET
|
Portage Biotech Inc.
Exploration and evaluation of strategic alternatives continuePausing patient enrollment in the ADPORT-601 clinical trial (adenosine 2A and 2B inhibitors)Discontinuing the iNKT clinical trial for...
Portage Biotech Announces 1-for-20 Reverse Stock Split
13. August 2024 07:00 ET
|
Portage Biotech Inc.
Portage Biotech Announces 1-for-20 Reverse Stock Split effective with the opening of trading on August 15, 2024, on The Nasdaq Capital Market
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
12. April 2024 08:01 ET
|
Portage Biotech Inc.
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
-Adenosine clinical development paused
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
26. März 2024 08:01 ET
|
Portage Biotech Inc.
WESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and...
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
28. Februar 2024 17:10 ET
|
Portage Biotech Inc.
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
Company focused on adenosine platform clinical development